Discussion on the immunoprophylaxis strategy of tuberculosis in China

doi:10.3969/j.issn.1000-6621.2014.11.001

Abstract

Abstract: At present, the domestic and foreign researchers basically reached an agreement on the ideas for the tuberculosis prevention and control. That is, in the case of no substitutes for currently used BCG, researchers should explore new prime vaccines, BCG prime-boosting vaccines and the vaccines for latent tuberculosis infection. These three types of new tuberculosis vaccines will focus on the populations with different immune markers. Therefore, how to screen the different types of people and then vaccinate with the corresponding vaccines is a key point in the TB control. The authors discussed on the above issues and try to propose the views on the immunoprophylaxis strategy of tuberculosis in China.

Key words: Tuberculosis/prevention &, control, BCG vaccine, Vaccination

LU Jin-biao, ZHAO Ai-hua, WANG Guo-zhi, XU Miao. Discussion on the immunoprophylaxis strategy of tuberculosis in China[J]. Chinese Journal of Antituberculosis, 2014, 36(11): 927-929. doi: 10.3969/j.issn.1000-6621.2014.11.001

References

［1］Aggerbeck H，Giemza R，Joshi P，et al. Randomised clinical trial investigating the specificity of a novel skin test (C-Tb) for diagnosis of M. tuberculosis infection. PLoS One，2013，8(5): e64215.
［2］Du WX，Chen BW，Lu JB，et al. Preclinical study and phase I clinical safety evaluation of recombinant Mycobacterium tuberculosis ESAT6 protein. Med Sci Monit Basic Res,2013，19: 146-152.
［3］都伟欣，陈保文，卢锦标，等. 重组结核分枝杆菌 ESAT6-CFP10蛋白与 PPD 皮肤试验的动物实验比较. 中华微生物学和免疫学杂志，2013，33(12): 911-915.
［4］Hart PD，Sutherland I. BCG and vole bacillus vaccines in the prevention of tuberculosis in adolescence and early adult life. Br Med J，1977，2(6082): 293-295.
［5］Tverdal A，Funnemark E. Protective effect of BCG vaccination in Norway 1956—1973. Tubercle，1988，69(2): 119-123.
［6］Colditz GA，Berkey CS，Mosteller F，et al. The efficacy of bacillus Calmette-Guérin vaccination of newborns and infants in the prevention of tuberculosis: meta-analyses of the published literature. Pediatrics，1995，96(1Pt 1): 29-35.
［7］Sterne JA，Rodrigues LC，Guedes IN. Does the efficacy of BCG decline with time since vaccination? Int J Tuberc Lung Dis，1998，2(3): 200-207.
［8］Barreto ML，Cunha SS，Pereira SM，et al. Neonatal BCG protection against tuberculosis lasts for 20 years in Brazil. Int J Tuberc Lung Dis，2005，9(10): 1171-1173.
［9］Aronson NE，Santosham M，Comstock GW，et al. Long-term efficacy of BCG vaccine in American Indians and Alaska Natives: A 60-year follow-up study. JAMA，2004，291(17): 2086-2091.
［10］Trial of BCG vaccines in south India for tuberculosis prevention: first report—Tuberculosis Prevention Trial. Bull World Health Organ, 1979，57(5):819-827.
［11］赵爱华，卢锦标，王国治. 我国结核病新疫苗研究策略的探讨. 中华微生物学和免疫学杂志，2013，33(12): 885-892.
［12］Mangtani P，Abubakar I，Ariti C，et al. Protection by BCG vaccine against tuberculosis: a systematic review of randomized controlled trials. Clin Infect Dis，2014，58(4): 470-480.
［13］王化金，周长山，隗合平，等. 停止卡介苗复种后儿童青少年结核感染及发病的研究. 中国防痨杂志，2001，23(2): 81-84.
［14］Rodrigues LC，Pereira SM，Cunha SS，et al. Effect of BCG revaccination on incidence of tuberculosis in school-aged children in Brazil: the BCG-REVAC cluster-randomised trial. Lancet，2005，366(9493): 1290-1295.
［15］Randomised controlled trial of single BCG, repeated BCG, or combined BCG and killed Mycobacterium leprae vaccine for prevention of leprosy and tuberculosis in Malawi. Karonga Prevention Trial Group. Lancet，1996，348(9019): 17-24.
［16］陈保文，沈小兵，都伟欣，等. 我国卡介苗保护力评价参考体系建立的探讨. 中国防痨杂志，2012，34(3): 150-153.
［17］Tameris MD，Hatherill M，Landry BS，et al. Safety and efficacy of MVA85A, a new tuberculosis vaccine, in infants previously vaccinated with BCG: a randomised, placebo-controlled phase 2b trial. Lancet，2013，381(9871): 1021-1028.
［18］全国结核病流行病学抽样调查技术指导组. 第四次全国结核病流行病学抽样调查报告. 中华结核和呼吸杂志，2002，25(1): 3-7.
［19］Orme IM. Safety issues regarding new vaccines for tuberculosis, with an emphasis on post-exposure vaccination. Tuberculosis (Edinb)，2006，86(1): 68-73.

[1]	Liu Juxiu, Zhang Jianhua, Wen Junjun, Jiang Xiaoshuang. Analysis and trend prediction of Mycobacterium tuberculosis drug resistance in Jilin City [J]. Chinese Journal of Antituberculosis, 2025, 47(3): 348-354.
[2]	Chen Wei, Li Xue, Liu Xiaoqiu, Li Yuhong, Ni Ni, Zhang Hui, Zhao Yanlin. Interpretation and explanation about the National Tuberculosis Prevention and Control Plan (2024—2030) [J]. Chinese Journal of Antituberculosis, 2025, 47(2): 130-136.
[3]	Rao Lixin, Wu Zheyuan, Chen Jing, Mao Dan, Liu Xinghang, Shen Xin, Chen Xin. Construction, application and prospect of integrated management information system for tuberculosis prevention and control in Shanghai [J]. Chinese Journal of Antituberculosis, 2025, 47(1): 18-21.
[4]	Huang Xian, Meng Weiyu, Luo Tao, Zhang Weihua, Li Xinyan, Lai Yanfen, Guo Hongge, Tang Vengkai, Lai Xiaoyu, Li Kefeng, Huang Mingxing. Comparative study and suggestions on the return to school policy of students with tuberculosis [J]. Chinese Journal of Antituberculosis, 2024, 46(9): 998-1005.
[5]	Li Meng, Gao Qian. New challenges in tuberculosis control: startling new findings on aerosol detection [J]. Chinese Journal of Antituberculosis, 2024, 46(7): 739-742.
[6]	Fan Xiaolei, Maiwulajiang·Yimamu , Peng Xiaowang, Hu Pengyuan, Wang Yanjie, Alimire·Abulimiti , Mairihaba·Kamili , Wang Senlu, Xiang Yang. Analysis of the incidence and influencing factors of household close contacts of pulmonary tuberculosis patients in Kashgar, Xinjiang Uygur Autonomous Region, 2018—2021 [J]. Chinese Journal of Antituberculosis, 2024, 46(4): 390-396.
[7]	Wang Chenyuan, Wang Shanshan, Wang Sainan, Shao Ge, Cao Jiayi, Xiong Haiyan, Hu Yi. Evaluation of the effectiveness of cerebrospinal fluid characteristics indicators in assisting rapid screening of tuberculous meningitis [J]. Chinese Journal of Antituberculosis, 2024, 46(3): 311-317.
[8]	Shu Wei, Guo Yusun, Li Shanshan, Pang Yu, Liu Yuhong, Mei Yang. Analysis of tuberculosis prevalence and control along the China-Proposed Belt and Road Initiative [J]. Chinese Journal of Antituberculosis, 2024, 46(3): 318-324.
[9]	Xia Lan, Liu Shuang, Li Ting, Lu Jia, Wang Danxia, Zhang Linglin. Analysis of screening of close contacts of pathogenic positive pulmonary tuberculosis patients in Sichuan Province from 2018 to 2022 [J]. Chinese Journal of Antituberculosis, 2024, 46(2): 178-182.
[10]	Jiang Xiaoying, Liu Jing, Zhang Zhiguo, Zhang Wen, Gao Mengqiu, Yang Xinting, Mi Fengling. Investigation and analysis of 196 newly diagnosed etiologically positive pulmonary tuberculosis patients on knowledge of tuberculosis infection control [J]. Chinese Journal of Antituberculosis, 2024, 46(2): 213-220.
[11]	Gong Fang, Tan Shouyong, Bao Wanling, Liu Guobiao. Analysis of screening results of close contacts of patients with etiologically negative pulmonary tuberculosis in Yuexiu District,Guangzhou City [J]. Chinese Journal of Antituberculosis, 2024, 46(12): 1485-1489.
[12]	Wang Xueyu, Shi Wenhui, Li Qi, Jing Wei, Chu Naihui, Nie Wenjuan. Efficacy and safety of Baidiziyin Pill and Shenqiyifei Pill in adjuvant treatment of susceptible pulmonary tuberculosis patients: a national randomized controlled multicenter clinical study [J]. Chinese Journal of Antituberculosis, 2024, 46(11): 1306-1312.
[13]	Daniel P. Chin, Zheng Zhijie. China can eliminate tuberculosis [J]. Chinese Journal of Antituberculosis, 2024, 46(10): 1185-1187.
[14]	Sun Huijuan, Chen Wei, Zhao Yanlin. The role of community in tuberculosis prevention and control [J]. Chinese Journal of Antituberculosis, 2024, 46(1): 23-28.
[15]	Zhou Wenyong, Wen Zexuan, Gao Mengxian, Li Tao, Zhang Hui, Wang Weibing. Prediction of the effectiveness and impact of the free healthcare policy for tuberculosis in China [J]. Chinese Journal of Antituberculosis, 2023, 45(9): 845-856.